{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:54:49Z","timestamp":1788317689922,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychogeriatrics"],"published-print":{"date-parts":[[2024,5]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Current evidence for the management of symptoms associated with dementia with Lewy bodies (DLB) using donepezil is limited. We conducted a meta\u2010analysis of three randomised controlled trials of donepezil in patients with DLB to investigate the overall efficacy of donepezil on Mini\u2010Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), and Clinician's Interview\u2010Based Impression of Change\u2010plus Caregiver Input (CIBIC\u2010plus).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A meta\u2010analysis was performed using the data of 312 patients administered placebo or 10 mg donepezil. Overall mean score differences for MMSE, NPI\u20102, and NPI\u201010 from baseline to week 12 and their 95% confidence intervals (CI) were estimated. For CIBIC\u2010plus, which was transformed from a seven\u2010point grade to a dichotomous outcome (improvements\/no improvements), odds ratio (OR) and its 95% CI were estimated. Random\u2010effects models were used, and heterogeneity was evaluated using the Cochrane's Q test and I\n 2<\/jats:sup>\n statistic.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Heterogeneity was suspected for NPI\u20102 (\n P<\/jats:italic>\n \u2009<\u20090.05; I\n 2<\/jats:sup>\n \u2009=\u200987.2%) and NPI\u201010 (\n P<\/jats:italic>\n \u2009<\u20090.05; I\n 2<\/jats:sup>\n \u2009=\u200967.7%) while it was not suspected for MMSE (\n P<\/jats:italic>\n \u2009=\u20090.23; I\n 2<\/jats:sup>\n \u2009=\u200932.4%) and CIBIC\u2010plus (\n P<\/jats:italic>\n \u2009=\u20090.26; I\n 2<\/jats:sup>\n \u2009=\u200919.8%). The overall mean MMSE score difference (mean difference: 1.50; 95% CI, 0.67\u20132.34) and the overall odds of improving CIBIC\u2010plus (OR: 2.20; 95% CI, 1.13\u20134.26) from baseline to week 12 were higher in the donepezil group than in the placebo group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Results of our meta\u2010analysis indicated overall efficacy of donepezil on cognitive impairment and global clinical status in patients with DLB.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/psyg.13101","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:49:01Z","timestamp":1709599741000},"page":"589-596","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Donepezil for dementia with Lewy bodies: meta\u2010analysis of multicentre, randomised, double\u2010blind, placebo\u2010controlled phase\n II<\/scp>\n ,\n III<\/scp>\n , and,\n IV<\/scp>\n studies"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-9948","authenticated-orcid":false,"given":"Etsuro","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Behavioural Neurology and Neuropsychiatry Osaka University United Graduate School of Child Development Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Osaka University Graduate School of Medicine Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Ohdake","sequence":"additional","affiliation":[{"name":"Clinical Planning and Development Department Medical HQs, Eisai Co. Ltd Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"189","article-title":"\"mini\u2010mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein MF","year":"1975","journal-title":"J Psychiatr Res"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo\u2010controlled trial","volume":"72","author":"Mori E","year":"2012","journal-title":"Ann Neurol"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo\u2010controlled, confirmatory phase III trial","volume":"7","author":"Ikeda M","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"e_1_2_8_5_1","unstructured":"MoriE IkedaM IsekiEet al.Efficacy and safety of donepezil in patients with dementia with Lewy bodies: Results from a 12\u2010week multicenter randomized double\u2010blind and placebo\u2010controlled Phase IV study in Press."},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings JL","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","article-title":"The neuropsychiatric inventory: assessing psychopathology in dementia patients","volume":"48","author":"Cummings JL","year":"1997","journal-title":"Neurology"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"pyv086","DOI":"10.1093\/ijnp\/pyv086","article-title":"Cholinesterase inhibitors for Lewy body disorders: a meta\u2010analysis","volume":"19","author":"Matsunaga S","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological management of Lewy body dementia: a systematic review and meta\u2010analysis","volume":"172","author":"Stinton C","year":"2015","journal-title":"Am J Psychiatry"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith IG","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium","volume":"65","author":"McKeith IG","year":"2005","journal-title":"Neurology"},{"key":"e_1_2_8_12_1","first-page":"175","article-title":"Content validity and inter\u2010rater reliability of the cognitive fluctuation inventory","volume":"66","author":"Hashimoto M","year":"2014","journal-title":"Brain Nerve"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1819.2006.01485.x","article-title":"Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open\u2010label study","volume":"60","author":"Mori S","year":"2006","journal-title":"Psychiatry Clin Neurosci"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn MM","year":"1967","journal-title":"Neurology"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/089198879600900404","article-title":"Clinical evaluation of global change in Alzheimer's disease: identifying consensus","volume":"9","author":"Olin JT","year":"1996","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"e_1_2_8_16_1","unstructured":"LeberP.Guidelines for the Clinical Evaluation of Antidementia Drugs First Draft. November 8 1990. Food and Drug Administration."},{"key":"e_1_2_8_17_1","unstructured":"European Agency for the Evaluation of Medicinal Products.Note for guidance on medicinal products in the treatment of Alzheimer's disease. EMEA Guideline CPMP\/EWP\/553\/95 1997."},{"key":"e_1_2_8_18_1","unstructured":"European Agency for the Evaluation of Medicinal Products.Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. EMEA Guideline CPMP\/EWP\/553\/95 Rev1 2008."},{"key":"e_1_2_8_19_1","first-page":"835","article-title":"Guidelines for clinical evaluation of antidementia","volume":"29","author":"Homma A","year":"1998","journal-title":"Pharm Regul Sci"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.archger.2008.10.001","article-title":"Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)","volume":"49","author":"Ricci M","year":"2009","journal-title":"Arch Gerontol Geriatr"}],"container-title":["Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/psyg.13101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T21:12:06Z","timestamp":1737407526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/psyg.13101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/psyg.13101"],"URL":"https:\/\/doi.org\/10.1111\/psyg.13101","archive":["Portico"],"relation":{},"ISSN":["1346-3500","1479-8301"],"issn-type":[{"value":"1346-3500","type":"print"},{"value":"1479-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"2023-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}